Baidu
map

JAMA:CYP2C19Lof携带患者与基因型指导的抗血小板药物治疗策略

2020-08-26 MedSci原创 MedSci原创

研究认为,对于携带CYP2C19 LOF突变的急性冠状动脉综合征或稳定型冠状动脉疾病患者,根据基因型指导选择P2Y12抑制剂治疗策略效果不显著

近日研究人员考察了CYP2C19Lof携带者接收基因型指导的口服P2Y12抑制剂治疗策略对PCI后患者预后的影响。
 
 
5302名因急性冠状动脉综合征(ACS)或稳定型冠状动脉疾病(CAD)接受PCI患者参与研究,随机接受基因型指导的P2Y12抑制剂治疗(n=2652),其中CYP2C19 LOF携带患者接受替卡格雷,而非携带患者接受氯吡格雷,另外2650名患者接受常规的氯吡格雷治疗,持续12个月。研究的主要终点是12个月中血管死亡、心肌梗死、中风、支架血栓形成和严重缺血反复的复合终点。次要终点为12个月出血事件。
 
患者平均年龄62岁,女性占25%,其中ACS患者占82%,94%的患者完成研究。总计1849名CYP2C19 LOF突变携带患者,其中903人接受基因型指导的替卡格雷治疗,932人接受常规氯吡格雷治疗。基因型指导组中,903名CYP2C19 LOF携带患者中35人出现主要终点事件(4.0%),而常规治疗组946名携带者中54人出现终点事件(5.9%,风险比0.66)。11项预先设定的次要终点中,组间差异不显著,其中指导组CYP2C19 LOF携带患者的出血事件发生率为1.9%,常规治疗组为1.6%(HR=1.22)。对于所有参与者,基因指导组113人出现终点事件(4.4%),常规组135人(5.3%,HR=0.84)。
 
 
研究认为,对于携带CYP2C19 LOF突变的急性冠状动脉综合征或稳定型冠状动脉疾病患者,根据基因型指导选择P2Y12抑制剂治疗策略效果不显著。
 
原始出处
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-11-02 30397604
  4. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms4000002082197205

    好资料

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    相关资讯请继续分享,谢谢

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    很好很详细,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55753, encryptionId=e00855e5387, topicName=抗血小板药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 25 05:53:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890877, encodeId=aa7118908e7fb, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 20 08:53:55 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933936, encodeId=48a61933936f9, content=<a href='/topic/show?id=aa17556681' target=_blank style='color:#2F92EE;'>#CYP2C19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5566, encryptionId=aa17556681, topicName=CYP2C19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 02 04:53:55 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776711, encodeId=3a961e767117b, content=<a href='/topic/show?id=fbf78905420' target=_blank style='color:#2F92EE;'>#血小板药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89054, encryptionId=fbf78905420, topicName=血小板药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ff838995252, createdName=songbq, createdTime=Sun Jan 31 10:53:55 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814194, encodeId=be6a81419458, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:20:12 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814010, encodeId=53ee8140102a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:09:46 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813948, encodeId=1ff981394873, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813889, encodeId=bdae81388905, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:19 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813671, encodeId=d2478136e1ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:49:44 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036242, encodeId=2a4e103624238, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:53:55 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-26 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

BMJ:肌钙蛋白、年龄与患者预后

研究认为,肌钙蛋白水平高于正常上限人群的死亡风险增加,且不受年龄的影响,特别是阳性患者在检测后前几周内集中死亡风险极高

JAMA:替格瑞洛单药vs替格瑞洛+阿司匹林对ACS支架患者不良临床事件的影响

对于接受药物洗脱支架治疗的ACS患者,在3个月的双重抗血小板治疗后转为替卡格雷单药治疗可降低大出血和心血管事件风险

JAMA Intern Med:PCI后ACS患者主要冠状动脉不良事件的预防——替卡格雷vs氯吡格雷

研究发现,PCI后,使用替卡格雷或氯吡格雷预防主要冠状动脉不良事件的效果相当,但替卡格雷使用人群的出血和呼吸困难风险增加

Lancet Diabetes Endo:alirocumab可大幅降低新近ACS患者后继心血管事件风险

研究认为,对于近期发生急性冠状动脉综合征的患者,接受alirocumab治疗可大幅降低患者后继心血管事件风险

ACS病因就是冠脉斑块破裂?没那么简单!这些病因你想到过吗?

下面共有6个ACS的病例,您觉得他们的病因是什么呢?

中国ACS患者血脂管理的现状与挑战

为进一步优化中国急性冠脉综合征(Acute coronary syndrome,ACS)患者全程管理,尤其是其长期血脂管理。2019欧洲心脏病学会(ESC)年会期间来自中国的三位心血管病学专家:北京大学第一医院霍勇教授、复旦大学中山医院葛均波院士以及中国人民解放军总医院陈韵岱教授与多位欧洲专家共同参与了“中欧ACS标准化管理学术交流启动会”。三位专家在会上也对中国ACS患者全程管理,尤其是血脂管理

Baidu
map
Baidu
map
Baidu
map